News | Cath Lab | June 19, 2019

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics

Study shows decreased treatment time and improved patient outcomes with new innovative approach

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics

June 19, 2019 — Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR), pressure distal/pressure aortic (Pd/Pa) alongside fractional flow reserve (FFR) post-percutaneous coronary intervention (PCI). This prospective study validates the diagnostic accuracy of Pd/Pa in identifying residual ischemia post-intervention against the reference standard, FFR. The study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

PCI is a nonsurgical procedure that improves blood flow to the heart by using a stent to open up blood vessels. Since 1998, more than 17.5 million coronary angiography and PCI procedures have been performed in the United States (Journal of the American College of Cardiology).

While the value of FFR (a way to measure coronary pressure drop across a stenosis; synonymous to flow under maximal hyperemia) to determine appropriateness of revascularization is well-established and incorporated into current guidelines, there is a growing body of evidence supporting the role of remeasuring FFR after intervention. It has been shown that almost 20-30 percent of patients continue to have residual ischemia (suboptimal flow) after successful stenting as determined by angiography — the current standard for determining procedural success. Furthermore, post-PCI FFR has been associated with long-term cardiac outcomes in multiple studies including post hoc analyses of the pivotal FAME trials.

Despite the robust evidence base, use of FFR in general is very low, especially post-PCI. Multiple factors including additional procedure time, cost and patient side effects have been cited as potential reasons. Study authors sought to build on this body by evaluating and validating the diagnostic performance of a non-hyperemic index (Pd/Pa), universally available on all pressure wire platforms, against the current “gold standard” of FFR post-PCI.

The study evaluated more than 1,200 patients and 1,600 vessels, comparing accuracy of Pd/Pa pre-and-post PCI against FFR. The diagnostic accuracy and comparative performance of Pd/Pa was then prospectively validated in 230 patients and 264 vessels against the reference standard FFR in identifying ischemia (<0.80) post-intervention in an ongoing registry (PROPER PCI="Post-PCI Registry Of Physiological Effects of Revascularization") to test the concept of “functionally optimized coronary intervention.”

Results showed that Pd/Pa had a significant linear correlation between Pd/Pa and FFR. In the prospective validation cohort, a Pd/Pa value of <0.90 demonstrated excellent diagnostic performance against FFR in identifying residual ischemia (FFR<0.80) with an area under curve 0.91 (sensitivity 76 percent and specificity 92 percent)

“We strongly believe that the best result of a PCI is not only a successful stent implantation but the demonstration that improved blood flow has been established and ischemia eliminated, the principal mechanism by which PCI improves symptoms and clinical outcomes in patients. The concept being functionally optimized revascularization,” said lead author Abdul Hakeem, M.D., FSCAI, Rutgers Robert Wood Johnson Medical School in New Brunswick, N.J. “The results of our study provide clinicians with an accurate instrument to gauge the physiological success of PCI, which is associated with reduced treatment times, decreased costs and potentially improved clinical outcomes. We believe that a hybrid approach using Pd/Pa generally and FFR in selected patients (those with Pd/Pa<0.90) post PCI will improve the functional and likely clinical outcomes of percutaneous interventions.”

The authors call for physicians to routinely measure Pd/Pa after intervention to establish the physiological success of PCI.

For more information: www.scai.org

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init